Multimodality Approach to Management of Stage III Non-Small Cell Lung Cancer

被引：8
作者：
Scarpaci, Anthony [1 ]
Mitra, Priya [1 ]
Jarrar, Doraid [1 ]
Masters, Gregory A. [2 ]
机构：
[1] Albert Einstein Med Ctr Philadelphia, Philadelphia, PA 19141 USA
[2] Helen F Graham Canc Ctr, Newark, DE 19713 USA
来源：
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA | 2013年 / 22卷 / 02期
关键词：
Non small cell lung cancer; Neoadjuvant treatment; Multimodality approach; CHEMOTHERAPY; CARBOPLATIN; PACLITAXEL; SURGERY; TRIAL;
D O I：
10.1016/j.soc.2012.12.014
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Multimodality Approach to Management of Stage Ill Non Small Cell Lung Cancer Anthony Scarpaci, Priya Mitra, Doraid Jarrar, and Gregory A. Masters Stage ill non small cell lung cancer represents a heterogeneous group of patients who are best managed with a multidisciplinary approach, including evaluation for surgical, radiation, and chemotherapeutic options.
引用
收藏
页码：319 / +
页数：11
相关论文
共 50 条
  • [31] Stage III non-small cell lung cancer: escalation matters, but how?
    Hegde, Aparna Madhukeshwar
    Walker, Paul Raymond
    TRANSLATIONAL LUNG CANCER RESEARCH, 2018, 7 : S107 - S110
  • [32] Taxanes in the treatment of advanced (stage III and IV) non-small cell lung cancer (NSCLC): Recent developments
    Simon, GR
    Bunn, PA
    CANCER INVESTIGATION, 2003, 21 (01) : 87 - 104
  • [33] Impact of Multimodality Treatment Sequence on Survival in Stage IIB Non-Small Cell Lung Cancer
    Stokes, Sean M.
    Massarweh, Nader N.
    Stringham, John R.
    Varghese, Thomas K.
    ANNALS OF THORACIC SURGERY, 2021, 112 (05) : 1559 - 1567
  • [34] The Landmark Series: Multimodality Therapy for Stage 3A Non-small Cell Lung Cancer
    Eby, Marcus E.
    Seder, Christopher W.
    ANNALS OF SURGICAL ONCOLOGY, 2020, 27 (08) : 3030 - 3036
  • [35] Phase I study to determine MTD of docetaxel and cisplatin with concurrent radiation therapy for stage III non-small cell lung cancer
    Li, You-quan
    Shi, An-hui
    Li, Fu-hai
    Yu, Rong
    Zhu, Guang-ying
    CHINESE JOURNAL OF CANCER RESEARCH, 2011, 23 (02) : 129 - 133
  • [36] Treatment patterns and long-term survival outcomes for patients with stage III non-small cell lung cancer: A retrospective study
    Kumari, Seema
    Karikios, Deme
    Yeghiaian-Alvandi, Roland
    Flynn, Peter
    Morgan, Lucy
    Kay, Lisa
    Ding, Pei
    ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2024, 20 (01) : 25 - 31
  • [37] The role of biomarkers in stage III non-small cell lung cancer
    Rosell, Rafael
    Gonzalez-Cao, Maria
    Ito, Masaoki
    Santarpia, Mariacarmela
    Aguilar, Andres
    Codony-Servat, Jordi
    EXPERT REVIEW OF RESPIRATORY MEDICINE, 2023, 17 (06) : 469 - 480
  • [38] Comparison of carboplatin and paclitaxel with or without bevacizumab in chemotherapeutic regimens for unresectable stage III non-small cell lung cancer
    Ding, T.
    Li, Z. -T.
    Zhang, X.
    Shi, Y. -T.
    EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES, 2017, 21 (16) : 3723 - 3729
  • [39] Chemoradiation for Unresectable Stage III Non-Small Cell Lung Cancer
    Price, Katharine A. R.
    Azzoli, Christopher G.
    Gaspar, Laurie E.
    SEMINARS IN THORACIC AND CARDIOVASCULAR SURGERY, 2008, 20 (03) : 204 - 209
  • [40] Surgical perspective in neoadjuvant chemoimmunotherapy for stage II-III non-small cell lung cancer
    Hong, Tao
    Sun, Teng
    Zhang, Miao
    Liu, Xinlong
    Yuan, Yanliang
    Dolo, Ponnie Robertlee
    Chen, Bi
    Zhang, Hao
    THORACIC CANCER, 2021, 12 (20) : 2796 - 2802
12345